Numerous published papers are investigating the utility of biomarkers in Idiopathic
Pulmonary Fibrosis (IPF) diagnosis, treatment, and outcome prediction. This chapter will …

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive parenchymal scarring,
leading to dyspnoea, respiratory failure and premature death. Although IPF is confined to the …

Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic, devastating, and progressive
lung disease that is characterized by fibrosis and respiratory failure. IPF holds high morbidity …

Idiopathic pulmonary fibrosis (IPF) diagnosis is still the diagnosis of exclusion. Differentiating
from other forms of interstitial lung diseases (ILDs) is essential, given the various therapeutic …

Making the diagnosis of idiopathic pulmonary fibrosis (IPF) can be challenging. However,
with the recent Food and Drug Administration (FDA) approval of anti-fibrotic therapies for …

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, debilitating, fibrotic lung
disease leading to respiratory failure, and ultimately to death. It is characterized by marked …

Idiopathic pulmonary fibrosis (IPF) is a chronic, debilitating, fibrotic lung disease leading to
respiratory failure and ultimately to death. Being the prototype of interstitial lung diseases …

Molecular biomarkers are highly desired in idiopathic pulmonary fibrosis (IPF), where they
hold the potential to elucidate underlying disease mechanisms, accelerated drug …

Despite major advances in the understanding of the pathogenesis of idiopathic pulmonary
fibrosis (IPF), diagnosis and management of the condition continue to pose significant …

Clinical management of IPF is unsatisfactory because of limited availability of truly effective
therapies, lack of accurate predictors of disease behavior and absence of simple short-term …